Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
KRYS compared with ARWR: revenue, margins and what each company keeps, and the suppliers and customers both name
KRYS
Krystal Biotech, Inc.
Change
Mkt cap
Revenue
Revenue
ARWR
Arrowhead Pharmaceuticals, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
KRYS
Krystal Biotech, Inc.
vs
ARWR
Arrowhead Pharmaceuticals, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
ARWR: latest quarter is a loss; flow not drawable.
Method
›
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
KRYS, solid
ARWR, dashed
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only KRYS
2
—
Hospitals and specialty distributors
unlisted
customer
—
Specialty pharmacy providers
unlisted
customer
Shared
0
No shared counterparties.
Only ARWR
4
AMGN
Amgen
customer
SRPT
Sarepta Therapeutics
customer
NVS
Novartis Pharma
customer
—
Takeda Pharmaceutical
unlisted
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
customer
KRYS
Krystal Biotech, Inc.
Change
324.31
▼
−0.07%
· post 330.32
Mkt cap
$9.8B
Revenue
$119M
Q2 FY26
Revenue
$389M
FY25
ARWR
Arrowhead Pharmaceuticals, Inc.
Change
60.49
0.00%
· post 59.64
Closed
Oct 30 '26
Mkt cap
$8.5B
Revenue
$75M
Q3 FY26
Revenue
$829M
FY25
vs
Compare
Closed
Oct 30 '26
KRYS
Krystal Biotech, Inc.
vs
ARWR
Arrowhead Pharmaceuticals, Inc.
324.31
▼
−0.07%
post 330.32
Price
60.49
0.00%
post 59.64
$9.8B
Mkt cap
$8.5B
Q2 FY26
$119M
Revenue
$75M
Q3 FY26
FY25
$389M
Revenue
$829M
FY25
Change
Change
KRYS
324.31
▼
−0.07%
vs
ARWR
60.49
0.00%
Closed
Oct 30 '26